Charles River Laboratories International, Inc. has reported its financial results for the fourth quarter and full-year 2025, as well as providing guidance for 2026. The company's revenue for the fourth quarter of 2025 was $994.2 million, a decrease of 0.8% from the same period in 2024. Full-year revenue for 2025 decreased by 0.9% to $4.02 billion compared to 2024.
On a non-GAAP basis, the company reported a decrease in net income for the fourth quarter of 2025, which was $118.8 million, down 13.0% from the same period in 2024. Diluted earnings per share on a non-GAAP basis were $2.39 for the fourth quarter of 2025, a decrease of 10.2% from the fourth quarter of 2024.
For the full-year 2025, on a non-GAAP basis, net income decreased by 3.9% to $512.3 million, and diluted earnings per share decreased by 0.4% to $10.28 from 2024.
The company also provided guidance for 2026, expecting non-GAAP earnings per share to increase by approximately 4% to 9% in 2026. Revenue growth for 2026 is projected to be flat to an increase of 1.5%. The guidance does not include the impact of planned divestitures that represent approximately 7% of annual revenue for 2025 and estimated 2026.
Segment results for the fourth quarter of 2025 showed a decrease in organic revenue for the Discovery and Safety Assessment (DSA) and Manufacturing Solutions segments, while the Research Models and Services (RMS) segment saw a 1.0% increase in revenue.
The company's CEO, James C. Foster, expressed optimism for positive demand trends continuing into 2026, focusing on strategic initiatives and scientific innovation to reinforce the company's position in the preclinical drug development market.
As a result of these announcements, the company's shares have moved -1.69% on the market, and are now trading at a price of $219.70. For the full picture, make sure to review CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s 8-K report.
